Hayashi Kazuhiko, Suzuki Osamu, Ichise Koji, Uchida Hirofumi, Anzai Makoto, Hasegawa Azusa, Shimizu Shinichi, Teshima Teruki, Fujimoto Jiro, Ogawa Kazuhiko
Department of Radiology, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Cancer Sci. 2025 Aug;116(8):2198-2207. doi: 10.1111/cas.70079. Epub 2025 May 25.
No classification methods to predict prognosis after carbon-ion radiotherapy for hepatocellular carcinoma have yet been reported. This study aimed to develop risk classification for cancer-specific survival (CSS) after carbon-ion radiotherapy for hepatocellular carcinoma using decision tree analysis as a data-mining method. In this single-center, retrospective study, we analyzed 90 consecutive patients with hepatocellular carcinoma treated with carbon-ion radiotherapy between 2018 and 2022. Liver tumors were irradiated at 60 Gy (relative biological effectiveness [RBE]) in four fractions. If the tumor was close to the gastrointestinal tract, it was irradiated at 60 Gy [RBE] in 12 fractions. Univariate and multivariate analyses of progression-free survival (PFS) and CSS were performed to assess patients' background and treatment-related factors. Decision tree analysis (DTA) was performed to assess prognostic factors for CSS that were significantly different in the multivariate analysis. The median follow-up period was 32.8 months for all patients and 35.6 months for survivors. Multivariate analysis identified dose fractionation and pretreatment alpha-fetoprotein values as significant prognostic factors for PFS and CSS. Moreover, clinical stage and pretreatment protein induced by vitamin K absence or antagonist ΙΙ values were significant prognostic factors for CSS. DTA revealed that the patients could be divided into three groups according to prognosis: low-risk, high-risk, and intermediate-risk. Consequently, the 3-year CSS rates for the low-, intermediate-, and high-risk groups were 100%, 73.3%, and 44.4%, respectively. DTA represents a new method for risk classification for CSS after carbon-ion radiotherapy for hepatocellular carcinoma based on tumor markers and clinical stage.
目前尚未有关于预测肝细胞癌碳离子放疗后预后的分类方法的报道。本研究旨在使用决策树分析作为数据挖掘方法,开发肝细胞癌碳离子放疗后癌症特异性生存(CSS)的风险分类。在这项单中心回顾性研究中,我们分析了2018年至2022年间连续接受碳离子放疗的90例肝细胞癌患者。肝脏肿瘤以60 Gy(相对生物效应[RBE])分4次照射。如果肿瘤靠近胃肠道,则以60 Gy [RBE]分12次照射。对无进展生存期(PFS)和CSS进行单因素和多因素分析,以评估患者的背景和治疗相关因素。进行决策树分析(DTA)以评估多因素分析中CSS的显著不同的预后因素。所有患者的中位随访期为32.8个月,存活患者为35.6个月。多因素分析确定剂量分割和治疗前甲胎蛋白值是PFS和CSS的显著预后因素。此外,临床分期和治疗前维生素K缺乏或拮抗剂II诱导的蛋白值是CSS的显著预后因素。DTA显示,患者可根据预后分为三组:低风险、高风险和中风险。因此,低风险、中风险和高风险组的3年CSS率分别为100%、73.3%和44.4%。DTA代表了一种基于肿瘤标志物和临床分期对肝细胞癌碳离子放疗后CSS进行风险分类的新方法。